^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CDK12 mutation

    i
    Entrez ID:
    51755
    Related biomarkers:
    Mutation
    CNA
    Related tests:
    Apply
    A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (NCT04826341)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/20/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2027
    BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)
    Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes (NCT05687110)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    07/06/2023
    Primary completion :
    08/01/2026
    Completion :
    09/01/2026
    BRCA1 • BRCA2 • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation
    Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis (NCT03047135)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    07/03/2024
    Initiation :
    03/01/2017
    Primary completion :
    05/24/2023
    Completion :
    05/01/2025
    BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A
    |
    BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
    |
    Lynparza (olaparib)
    Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations (NCI10217) (NCT03842228)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    11/21/2019
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN
    |
    PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Aliqopa (copanlisib)
    A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) (NCT02734004)
    Phase 1/2
    AstraZeneca
    Active, not recruiting
    Last update posted :
    05/10/2024
    Initiation :
    03/17/2016
    Primary completion :
    09/17/2021
    Completion :
    09/17/2025
    HER-2 • BRCA
    |
    HER-2 negative • CDK12 mutation • BARD1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab)
    Nivolumab in Biochemically Recurrent dMMR Prostate Cancer (CA209-76M) (NCT04019964)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    04/26/2024
    Initiation :
    01/13/2020
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    TMB • MSI • MLH1 • MSH6 • MSH2 • CDK12
    |
    MSI-H/dMMR • CDK12 mutation
    |
    Opdivo (nivolumab)
    Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO) (NCT04779151)
    Phase 2
    Gustave Roussy, Cancer Campus, Grand Paris
    Suspended
    Last update posted :
    03/26/2024
    Initiation :
    04/07/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2027
    HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • ARID2 • BARD1 • NBN • RAD54L • DRD
    |
    HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) (NCT04276376)
    Phase 2
    Gustave Roussy, Cancer Campus, Grand Paris
    Suspended
    Last update posted :
    03/26/2024
    Initiation :
    04/12/2019
    Primary completion :
    12/01/2024
    Completion :
    04/01/2025
    BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • IL2 • RAD51D • BARD1 • NBN • RAD54L • DRD
    |
    DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD
    |
    Tecentriq (atezolizumab) • Rubraca (rucaparib)
    Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID) (NCT03786796)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    03/05/2024
    Initiation :
    06/03/2019
    Primary completion :
    03/01/2025
    Completion :
    03/01/2026
    BRCA1 • BRCA2 • BAP1 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    Lynparza (olaparib)
    Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects (BRCAAway) (NCT03012321)
    Phase 2
    Northwestern University
    Active, not recruiting
    Last update posted :
    08/30/2023
    Initiation :
    01/12/2017
    Primary completion :
    12/16/2026
    Completion :
    01/16/2027
    BRCA1 • BRCA2
    |
    CDK12 mutation
    |
    Lynparza (olaparib) • abiraterone acetate • prednisone
    High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers (VA-BAT) (NCT05011383)
    Phase 2
    VA Office of Research and Development
    Recruiting
    Last update posted :
    08/17/2023
    Initiation :
    08/31/2021
    Primary completion :
    08/31/2026
    Completion :
    08/31/2027
    CDK12 • CHEK2
    |
    ATM mutation • CDK12 mutation • CHEK2 mutation
    M6620 (VX-970) in Selected Solid Tumors (NCT03718091)
    Phase 2
    Massachusetts General Hospital
    Completed
    Last update posted :
    07/07/2023
    Initiation :
    01/08/2019
    Primary completion :
    06/01/2020
    Completion :
    07/08/2020
    BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation
    |
    berzosertib (M6620)
    The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation (PROact) (NCT05167175)
    Phase 2
    Hongqian Guo
    Recruiting
    Last update posted :
    10/25/2022
    Initiation :
    03/01/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    Lynparza (olaparib) • abiraterone acetate • prednisone
    Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (CHANGEABLE) (NCT04508803)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    06/30/2022
    Initiation :
    09/14/2020
    Primary completion :
    11/20/2022
    Completion :
    12/28/2022
    HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • WRN • FANCM • FANCD2 • FANCE • FANCC
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • BLM mutation • CHEK1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation • CHEK1 expression
    |
    Herceptin (trastuzumab) • cisplatin • Zejula (niraparib) • Puyouheng (pucotenlimab)
    The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation (PROspect) (NCT05262608)
    Phase 2
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Un...
    Recruiting
    Last update posted :
    03/02/2022
    Initiation :
    12/07/2021
    Primary completion :
    02/26/2024
    Completion :
    04/26/2024
    BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    Lynparza (olaparib)
    Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi) (NCT05116579)
    Phase N/A
    Sun Yat-sen University
    Recruiting
    Last update posted :
    11/11/2021
    Initiation :
    10/31/2021
    Primary completion :
    03/31/2023
    Completion :
    08/31/2023
    BRCA1 • BRCA2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation • BRCA1 mutation + ATM mutation • CHEK1 expression
    Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With HRR Mutation and MSS (NCT04592211)
    Phase 1/2
    Yonsei University
    Not yet recruiting
    Last update posted :
    08/31/2021
    Initiation :
    10/01/2021
    Primary completion :
    12/31/2022
    Completion :
    05/31/2023
    HER-2 • BRCA1 • BRCA2 • HRD • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • paclitaxel
    Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer (NCT04272645)
    Phase 2
    University of Michigan Rogel Cancer Center
    Withdrawn
    Last update posted :
    07/15/2020
    Initiation :
    10/01/2020
    Primary completion :
    10/01/2022
    Completion :
    10/01/2022
    CDK12
    |
    CDK12 mutation
    |
    Tecentriq (atezolizumab) • Verzenio (abemaciclib)